Organogenesis (ORGO) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $115.2 million, up 6% year-over-year, driven by 7% growth in Advanced Wound Care and modest growth in Surgical & Sports Medicine.

• Net income for Q3 2024 was $12.3 million, a significant increase from the prior year, aided by a $6.5 million income tax benefit.

• Adjusted EBITDA for Q3 2024 was $13.4 million (12% margin), down from $16.0 million (14.7% margin) last year, reflecting higher operating expenses.

• Significant non-recurring charges in 2024 included an $18.8 million building impairment and a $4.0 million software write-down.

• Strategic progress included positive Phase 3 clinical trial results for ReNu and expanded clinical validation for NuShield and PuraPly products.

Financial highlights

• Advanced Wound Care revenue grew 7% to $108 million; Surgical & Sports Medicine revenue was $7.2 million, up 1% year-over-year.

• Gross profit for Q3 2024 was $88.4 million (77% margin), up from $82.7 million (76% margin) in Q3 2023.

• Operating income was $6.2 million, down 22% year-over-year; non-GAAP operating income was $7.1 million, down 35%.

• Adjusted net income for Q3 2024 increased 143% year-over-year to $12.9 million.

• Cash and equivalents at quarter-end were $94.9 million; net debt was $62.1 million.

Outlook and guidance

• FY 2024 net revenue expected between $455 million and $480 million, a 5%–11% increase year-over-year.

• Advanced Wound Care revenue guidance: $429–$452 million (6%–11% growth); Surgical & Sports Medicine: $26–$28 million (down 7% to up 1%).

• FY 2024 net loss projected between $12.3 million and $0.6 million; adjusted EBITDA expected between $31.7 million and $47.4 million.

• Guidance reflects potential Q4 disruption from LCDs, with final MAC ruling expected in Q4 and effective January 1, 2025.

• Management expects available cash, credit, and proceeds from preferred stock to fund operations for at least 12 months beyond the filing date.